Our co-founder and CEO @CaitlynBioE spoke with @ky_lahucik about our work developing a novel tumor-targeting platform for solid tumors - and how this approach opens up new possibilities for cancer treatment.
Read more in @endpts News👇
https://t.co/gcuPiet2Ur
My dad died from colon cancer in 2020, NFX bio principal Gita Bassman Reinitz lots two parents to cancer, so many people we know are effected by this horrible disease..
https://t.co/nXchuC7Mfz
1/ We’re excited to announce our official launch and the closing of a $6.5M seed round to advance our pipeline of targeted therapies for solid tumors. Learn more 👉
https://t.co/wjSYaEhzEg
We are thrilled to announce our latest investment in @TwoStepTx!
Read more about why we invested 👇
https://t.co/ERxSs6b8TB
💡 Enabling targeted delivery to virtually any solid tumor using a unique and modular polyspecific integrin-binding peptide.
👩💻 The Founder: @CaitlynBioE
📌 Location: San Francisco, CA
💰 Investment Stage: Seed
You can also read more in this article (shoutout to @ky_lahucik for the writeup!)
https://t.co/HY5Lc43zvT
Thrilled to share that @TwoStepTx has officially launched! With the closing of our seed round, we’ll be advancing our pipeline of targeted therapies for solid tumors.
Many thanks to our incredible co-founders and investors for their support. @CarolynBertozzi @CochranLab
5/ We launched from @Stanford Innovative Medicines Accelerator and are backed by investors led by @NFX with participation from @2048vc, Alexandria Venture Investments, @CooleyLLP affiliated fund GC&H Investments, and the family office of the founder of Arcadia Investment Partners
1/ We’re excited to announce our official launch and the closing of a $6.5M seed round to advance our pipeline of targeted therapies for solid tumors. Learn more 👉
https://t.co/wjSYaEhzEg
4/ Our work is guided by world-class academic-entrepreneurs at Stanford, including co-founders @CarolynBertozzi , Jennifer Cochran @CochranLab and Ron Levy.